Choroidal thickness after phacoemulsification: a nonrandomized comparison of postoperative topical ketorolac vs dexamethasone vs a combination of ketorolac–dexamethasone eyedrops
Leila Ghiasian1 *
- Eye Research center, the five senses institute, rassoul akram hospital, iran university of medical sciences, Tehran, Iran
Abstract: To compare the effect of topical dexamethasone vs
ketorolac vs combined dexamethasone–ketorolac after phacoemulsification
on choroidal thickness (CT).
Methods: Ninety-two eyes of 92 patients were assigned to the 3
groups after uneventful phacoemulsification: Group 1, dexamethasone;
Group 2, ketorolac; Group 3, combined
dexamethasone–ketorolac that applied topically. CT at subfoveal
(SFCT), nasal, and temporal as primary and central retinal thickness
(CRT) as secondary outcomes were measured preoperatively and
at 1 month, 3 months, and 6 months postoperatively using enhanced
depth imaging optical coherence tomography.
Results: Preoperative CT was similar between the groups (all
AU1 P > .05). The groups differed in pattern of changes in nasal
and temporal CT (both P < .001) although their changes of CRT
(P = .13) and SFCT (P = .55) over time were similar. The mean of
SFCT at 1 month, 3 months, and 6 months was significantly
higher than baseline in dexamethasone (P < .001 for all followups)
and combined (P < .001 for both 1 month and 3 months
and P = .03 for 6 months) groups, whereas it was not statistically
significant in the ketorolac group (P = .07). There was an increase
in the nasal and temporal CT in 3 groups, persisted at
6 months in dexamethasone (both P < .001) and ketorolac (both
P < .001) groups, whereas the change was not statistically
significant at 6 months in the combined group.
Conclusion: Dexamethasone and combined groups had statistically
significant changes of SFCT after phacoemulsification;
however, the ketorolac group did not. The pattern of SFCT changes
was similar between 3 groups.
